BRAF and neoplasm: Additionally, for patients with advanced solid tumors harboring a confirmed BRAF V600 mutation, treatment recommendations should be refined based on the specific tumor type and molecular pathological characteristics, such as the presence of MSI-H or high PD-L1 expression.50